PL367624A1 - Pharmaceutical formulation for the intramuscular administration of fulvestrant - Google Patents

Pharmaceutical formulation for the intramuscular administration of fulvestrant

Info

Publication number
PL367624A1
PL367624A1 PL02367624A PL36762402A PL367624A1 PL 367624 A1 PL367624 A1 PL 367624A1 PL 02367624 A PL02367624 A PL 02367624A PL 36762402 A PL36762402 A PL 36762402A PL 367624 A1 PL367624 A1 PL 367624A1
Authority
PL
Poland
Prior art keywords
fulvestrant
pharmaceutical formulation
intramuscular administration
intramuscular
administration
Prior art date
Application number
PL02367624A
Other languages
English (en)
Polish (pl)
Inventor
Julie Kay Cahill
Paul Richard Gellert
Alan Marshall Irving
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0116619.8A external-priority patent/GB0116619D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL367624A1 publication Critical patent/PL367624A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
PL02367624A 2001-07-07 2002-07-03 Pharmaceutical formulation for the intramuscular administration of fulvestrant PL367624A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0116619.8A GB0116619D0 (en) 2001-07-07 2001-07-07 Formulation
US31571101P 2001-08-30 2001-08-30

Publications (1)

Publication Number Publication Date
PL367624A1 true PL367624A1 (en) 2005-03-07

Family

ID=26246290

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02367624A PL367624A1 (en) 2001-07-07 2002-07-03 Pharmaceutical formulation for the intramuscular administration of fulvestrant

Country Status (15)

Country Link
EP (1) EP1406662A1 (is)
JP (1) JP2004534093A (is)
CN (1) CN1553815A (is)
AR (1) AR037138A1 (is)
BR (1) BR0210898A (is)
CA (1) CA2453111A1 (is)
CO (1) CO5560585A2 (is)
HU (1) HUP0400115A3 (is)
IL (1) IL159576A0 (is)
IS (1) IS7097A (is)
MX (1) MXPA04000028A (is)
NO (1) NO20040047L (is)
PL (1) PL367624A1 (is)
RU (1) RU2004102393A (is)
WO (1) WO2003006064A1 (is)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US8586092B2 (en) 2009-08-31 2013-11-19 Xi'an Libang Pharmaceutical Technology Co., Ltd. Fulvestrant nanosphere/microsphere and preparative method and use thereof
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600065B (zh) * 2012-03-31 2014-08-13 莱普德制药有限公司 一种氟维司群或其衍生物油性制剂及其制备方法
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
JP6682163B2 (ja) * 2016-04-06 2020-04-15 富士フイルム株式会社 医薬組成物
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
MX2018013414A (es) * 2016-05-06 2019-06-06 Eagle Pharmaceuticals Inc Formulaciones de fulvestrant y metodos para su uso.
CN109152785B (zh) 2016-05-31 2021-02-09 富士胶片株式会社 医药组合物
JP7220712B2 (ja) * 2017-11-08 2023-02-10 イーグル ファーマスーティカルズ、インク． フルベストラント製剤とその使用方法
US20210169897A1 (en) * 2017-12-07 2021-06-10 Nevakar Inc. Concentrated Fulvestrant Compositions
WO2019151353A1 (ja) * 2018-01-31 2019-08-08 富士フイルム株式会社 注射用製剤の製造方法
CN111481559B (zh) * 2019-01-25 2021-10-08 江苏恒瑞医药股份有限公司 一种高浓度的氟维司群组合物及其制备方法
US20220370359A1 (en) * 2019-12-11 2022-11-24 Shanghai Bocimed Pharmaceutical Co., Ltd. Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Also Published As

Publication number Publication date
IS7097A (is) 2004-01-05
CA2453111A1 (en) 2003-01-23
JP2004534093A (ja) 2004-11-11
MXPA04000028A (es) 2004-05-21
WO2003006064A1 (en) 2003-01-23
CO5560585A2 (es) 2005-09-30
NO20040047L (no) 2004-02-23
RU2004102393A (ru) 2005-03-27
BR0210898A (pt) 2004-06-22
IL159576A0 (en) 2004-06-01
EP1406662A1 (en) 2004-04-14
HUP0400115A2 (hu) 2004-06-28
AR037138A1 (es) 2004-10-27
CN1553815A (zh) 2004-12-08
HUP0400115A3 (en) 2005-11-28

Similar Documents

Publication Publication Date Title
IL156716A0 (en) Pharmaceutical formulation
HUP0401642A3 (en) Use of staurosporine derivatives for the preparation of pharmaceutical compositions
GB0118689D0 (en) Pharmaceutical formulation
HUP0204137A3 (en) Pharmaceutical composition comprising fulvestrant
HUP0400200A3 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
PL366432A1 (en) Pharmaceutical formulation
AU2002257582A1 (en) Pharmaceutical formulation
IL159576A0 (en) Pharmaceutical formulation for the intramuscular administration of fulvestrant
EP1406493A4 (en) ADMINISTRATION OF MEDIUM BY THE PEPT-2 TRANSPORTER
GB0103638D0 (en) Pharmaceutical formulations
IL161306A0 (en) Pharmaceutical formulation comprising (r)-bicalutamide
GB0105560D0 (en) Pharmaceutical formulations
HK1068277A1 (en) Pharmaceutical compositions comprising chelidonineor derivatives thereof
HUP0200253A2 (en) Pharmaceutical compositions for combination therapy
GB0201607D0 (en) Formulation for the administration of medicinal substances
GB0014851D0 (en) Novel pharmaceutical formulation
GB0104749D0 (en) Pharmaceutical formulation
GB0014947D0 (en) Novel pharmaceutical formulation
GB0014892D0 (en) Novel pharmaceutical formulation
GB0014883D0 (en) Novel pharmaceutical formulation
GB0317345D0 (en) Formulation for the administration of medicinal substances
GB0124712D0 (en) Pharmaceutical formulation
EP1414417A4 (en) PHARMACEUTICAL FORMULATION
HUP0103049A3 (en) Use of fluexetine for preparation of pharmaceutical compositions
GB0014869D0 (en) Novel pharmaceutical formulation

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)